Cart
sales@molnova.com
PBRM1-BD2-IN-3
CAS No. 2819989-58-5
PBRM1-BD2-IN-3( —— )
Catalog No. M35351 CAS No. 2819989-58-5
PBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 of 1.1 μM, used in anticancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 226 | In Stock |
|
| 5MG | 256 | In Stock |
|
| 10MG | 375 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 776 | In Stock |
|
| 100MG | 1042 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2102 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePBRM1-BD2-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionPBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 of 1.1 μM, used in anticancer research.
-
DescriptionPBRM1-BD2-IN-3 (compound 12) is a potent PBRM1-BD2 inhibitor with an IC50 value of 1.1 μM. PBRM1-BD2 Inhibitor can be used to research anticancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2819989-58-5
-
Formula Weight258.7
-
Molecular FormulaC14H11ClN2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=2C(NC(N1)C3=CC=CC=C3)=CC=CC2Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Shishodia S, et al. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. J Med Chem. 2022 Oct 13.?
molnova catalog
related products
-
dCBP-1
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
-
OTX015
OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. Phase 1.
-
TRIM24/BRPF1-IN-2
TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
